Opti: New microbial strain registrations

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the registration of five new microbial strains under the Budapest Treaty. This increases the number of strain registrations from three to eight.

The Budapest Treaty is an international treaty administered by the World Intellectual Property Organisation which enables the deposition of micro-organisms for the purposes of patent protection. This provides a reference point for filing and defending patents and establishing title during commercial discussions. Registration of these strains protects the advances made in developing novel sugars using OptiBiotix’s proprietary OptiBiotic® platform technology.

The five strains have been identified as having the potential to generate novel oligosaccharides (carbohydrates that consist of a small number of sugars). As announced on 9 July 2015, oligosaccharides from strains showing commercial potential are being scaled up, purified, and tested for their organoleptic (taste, texture, aftertaste) and microbiome modulating properties. This work is the final stages of the laboratory programme which will enable OptiBiotix to progress its pipeline of novel oligosaccharides to testing in human studies.

Stephen O’Hara, CEO of OptiBiotix, commented: “We are pleased to announce the registration of these strains which will protect the recent advances we have made in developing novel sugars. With our cholesterol product moving to pilot manufacture and our sugar development programmes moving towards clinical studies, we are making good progress in multiple product and partnering opportunities for compounds which modify the human microbiome to improve human health.”

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.